As someone who has personally experienced the devastating impact of ocular melanoma, I am deeply concerned about the National Institute for Health Care and Excellence's (NICE) decision to deny approval for Tebentafusp (Tebe/Kimmtrak) as a treatment option for people with uveal melanoma in stage IV cancer outside of the eye. This petition aims to urge NICE to reconsider their decision and prioritize the well-being of patients who desperately need this life-saving medication.

My own battle with ocular melanoma has made me acutely aware of the limited treatment options available, particularly when it comes to advanced stages of this aggressive disease. When faced with stage IV cancer, time becomes a precious commodity, and every potential avenue for treatment should be explored.

Tebentafusp has shown promising results in clinical trials, demonstrating its efficacy in treating uveal melanoma that has spread beyond the eye. Despite acknowledging the distressing impact this disease has on patients' lives, NICE deemed Tebentafusp too expensive relative to its perceived benefits. However, it is crucial that we challenge this assessment based on accurate facts and statistics.

According to a study published in The Lancet Oncology by Dr. X et al., Tebentafusp exhibited significant improvements in progression-free survival compared to alternative treatments currently available. Additionally, another study conducted by Dr. Y et al., published in Cancer Medicine Journal highlighted its potential as an effective immunotherapy option with manageable side effects.

It is disheartening that cost considerations are overshadowing patient welfare when making decisions about access to life-saving medications like Tebentafusp. We must remember that behind each statistic lies a real person fighting for their life – individuals like myself who have experienced firsthand how limited treatment options can affect quality of life.

By signing this petition, you are not only supporting my personal cause but also advocating for the thousands of individuals who are currently battling uveal melanoma in stage IV cancer. Together, we can make a difference and ensure that NICE reevaluates their decision, taking into account the potential benefits and impact Tebentafusp could have on patients' lives.

Let us stand united in our fight against uveal melanoma and demand that NICE approves Tebentafusp as a treatment option for those who need it most. Sign this petition today to help save lives and provide hope to those facing this challenging journey.

Thank you for your support!

[Your Name]